

Romano Danesi, MD, PhD

University of Pisa
+39-050-992632
r.danesi@med.unipi.it



Pharmacogenomics is strategic companion in current clinical development of novel anticancer agents. The identification of genetic markers predictive of clinical outcome is a potential key instrument for accurate patient stratification and personalized treatment. This approach is the main research interest of Romano Danesi, who received his M.D. degree in 1983 from the University of Pisa, Italy, and his Ph.D. degree in Pharmacology of Cancer Chemotherapy from the Superior School S. Anna, Pisa, Italy in 1988. Since 2003 he is visiting professor in the Molecular Pharmacology Section, Medicine Branch, NCI, Bethesda, MD and in the Cancer Center, Yale University, New Haven, CT. Dr. Danesi is board certified in Diseases of the Lung (1988), Clinical Pharmacology (2001) and Medical Oncology (2006) and he is full professor of Pharmacology since 2005 in the Department of Internal Medicine, University of Pisa. Dr Danesi is presently Chief of the Section of Cancer Pharmacology of Pisa University Hospital and Chair of the Ethics Committee of the same institution. Dr. Danesi's main research interests are rational and accelerated development of new drugs for cancer therapy, pharmacogenetic approach to treatment optimization, gene expression and proteomics, development of new genetic markers for disease prognosis, prediction of response and toxicity of anticancer agents. He also has a longstanding interest in clinical pharmacology and pharmacodynamics of anticancer agents. He is member of the Grant Review Committee of the European Commission, Swiss Group for Clinical Cancer Research (SAKK), and the Italian Ministry of Education, University and Research (MIUR).

Recent publications

Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, Rosell R. Pharmacogenomics in non-small-cell lung cancer chemotherapy. *Adv Drug Deliv Rev* 2009;61(5):408-17

Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. *Clin Cancer Res* 2008;14(11):3312-8

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. *Clin Cancer Res* 2008;14(6):1797-803